Intravenous Immunoglobulin in the Treatment of Salmonella Typhimurium Infections in Preterm Neonates

The purpose of this study was to determine the role of intravenous immunoglobulin (IVIG) administration in preterm neonates with S. typhimurium infection. A randomized trial of 47 preterm neonates with intestinal or extraintestinal S. tymphimurium infection was performed. Neonates were randomly divi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pediatrics 1994-06, Vol.33 (6), p.349-352
Main Authors: Gökalp, Ayse Sevim, Toksoy, Hayri Bozkurt, Türkay, Sadi, Bakici, Mustafa Zahir, Kaya, Rafet
Format: Article
Language:English
Subjects:
Bacterial diseases
Bacterial diseases of the digestive system and abdomen
Biological and medical sciences
Cefoperazone - administration & dosage
Cefoperazone - therapeutic use
Drug Therapy, Combination
Female
Human bacterial diseases
Humans
Immunoglobulins, Intravenous - administration & dosage
Immunoglobulins, Intravenous - therapeutic use
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases - drug therapy
Infectious diseases
Male
Medical sciences
Salmonella Infections - drug therapy
Salmonella typhimurium
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to determine the role of intravenous immunoglobulin (IVIG) administration in preterm neonates with S. typhimurium infection. A randomized trial of 47 preterm neonates with intestinal or extraintestinal S. tymphimurium infection was performed. Neonates were randomly divided into two groups: 22 neonates were only given cefoperazone (group 1); 25 neonates were given cefoperazone plus IVIG (group 2). IVIG was given at a dose of 500 mg/kg on days 1, 2, 3, and 8 after entry into the study. Following treatment, bacteremia, complications, mortality rate, recovery time, and duration of antimicrobial therapy were evaluated in two groups. Bacteremia was found in 31.4% in group 1 and 8% in group 2 (P
ISSN:0009-9228
1938-2707
DOI:10.1177/000992289403300607